ERBB2 and breast cancer: Lovastatin also modulates PM rigidity and fluidity, promoting endocytic degradation of the tyrosine kinase receptor ErbB2 and thus synergizing with the tyrosine kinase inhibitor lapatinib to impair ErbB2-positive breast cancer growth (Zhang et al., 2019).